drugset

drugset / Trial / NCT04008069

Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis

NCT04008069 ↗

Phase 2 Completed 16 enrolled Stanford University

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to compare the effectiveness and the safety of sarilumab in patients with glucocorticoid-dependent sarcoidosis.

Timeline

Start: 2019-09-03
Primary completion: 2022-07-26
Completion: 2022-09-09

Publications

Baker MC, Horomanski A, Wang Y, Liu Y, Parsafar S, Fairchild R, Mooney JJ, Raj R, Witteles R, Genovese MC. A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis. Rheumatology (Oxford). 2024 May 2;63(5):1297-1304. doi: 10.1093/rheumatology/kead373.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sarilumab	Monoclonal antibody	200 mg	Subcutaneous

Indications